Company Directory / Biotechnology

PrivateFor profitBiotechnologySouth Korea
Intocell is a biotechnology company that develops antibody drug conjugate (ADC) platform technologies.
Size
1-10 people: larger than 0% of companies with a size listed
Age
11 years old.
Reach
No web traffic ranking listed.
BiotechnologyInformation TechnologyMedical
Funding, as listed
$35B currency not stated
What the source datasets report. We have not watched these rounds ourselves.
Everything the source datasets list about Intocell, field by field. Contact details are held but never shown.
The company
Where
Size and reach
Funding, as listed
About this record
Growth, as the source summarises it
Intocell may be growing as it has entered into a collaboration with Samsung Bioepis to co-develop ADC drugs, which indicates a strategic partnership that could enhance its product development capabilities. This collaboration with a significant player in the biotechnology industry suggests an expansion of Intocell's operational activities and potential access to new resources. The partnership is likely to contribute to Intocell's revenue stream and could be indicative of the company's positive trajectory in the biotechnology sector.
Summaries written by the source dataset, not by us, and not checked.
Biotechnology in South Korea.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 13,309 companies in South Korea and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.